| Business Summary | | Covalent
Group,
Inc.
is
a
total
research
management
organization
that
designs
and
manages
clinical
trials
in
the
drug
and
device
development
process
and
with
associated
cost
containment
and
quality
of
care
components.
The
Company
specializes
in
Phase
I
through
IV
clinical
trials
for
pharmaceutical
companies.
The
Company
offers
a
full
array
of
integrated
services
including
study
design,
clinical
trial
monitoring
and
management,
data
management,
biostatistical
analysis
and
regulatory
affairs
services.
The
Company
is
structured
to
deliver
customized
high
quality
solutions
to
its
Fortune
500
and
other
clients. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Covalent
Group,
Inc.
is
a
total
research
management
organization
that
designs
and
manages
clinical
trials
in
the
drug
and
device
development
process
with
associated
cost
containment
and
quality
of
care
components.
For
the
six
months
ended
6/30/01,
revenues
rose
26%
to
$8.5
million.
Net
income
rose
25%
to
$1.1
million.
Results
reflect
an
increase
in
the
number
of
clinical
development
projects
in
process,
partially
offset
by
higher
net
interest
expense. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Anthony Cerami, Ph.D., 60 Chairman | -- | Kenneth Borow, M.D., 52 CEO,
Chief Medical Officer | $267K | Joseph Delikat, 54 Director,
Principal Accounting Officer | -- | James Cappola, M.D., Ph.D., 57 Exec.
VP, CMO | 133K | David Weitz, 50 CIO,
Sec., Treasurer | 135K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|